Focused On-demand Library for Lysosome membrane protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14108

UPID:

SCRB2_HUMAN

Alternative names:

85 kDa lysosomal membrane sialoglycoprotein; CD36 antigen-like 2; Lysosome membrane protein II; Scavenger receptor class B member 2

Alternative UPACC:

Q14108; B4DKD8; E7EM68; Q53Y63

Background:

Lysosome membrane protein 2, also known as 85 kDa lysosomal membrane sialoglycoprotein, CD36 antigen-like 2, Lysosome membrane protein II, and Scavenger receptor class B member 2, plays a crucial role in cellular processes. It acts as a lysosomal receptor for glucosylceramidase targeting and serves as a receptor for enterovirus 71. This protein's involvement in these pathways underscores its importance in maintaining cellular homeostasis and defense mechanisms.

Therapeutic significance:

Lysosome membrane protein 2 is implicated in Epilepsy, progressive myoclonic 4, with or without renal failure, a disorder characterized by action and reflex myoclonus, epileptic seizures, and progressive neurodegeneration. Understanding the role of this protein could open doors to potential therapeutic strategies, especially considering its association with renal failure in some cases.